Compare LCNB & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | MDWD |
|---|---|---|
| Founded | 1877 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.5M | 212.1M |
| IPO Year | 1999 | 2013 |
| Metric | LCNB | MDWD |
|---|---|---|
| Price | $15.97 | $17.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 17.7K | ★ 68.2K |
| Earning Date | 04-22-2026 | 05-20-2026 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | ★ 68.04 | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $6,445,000.00 | N/A |
| Revenue This Year | $8.50 | $48.92 |
| Revenue Next Year | $3.66 | $35.04 |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.75 | $14.90 |
| 52 Week High | $17.89 | $22.51 |
| Indicator | LCNB | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 55.82 |
| Support Level | $15.92 | $16.68 |
| Resistance Level | $16.44 | $18.49 |
| Average True Range (ATR) | 0.48 | 0.56 |
| MACD | -0.08 | 0.03 |
| Stochastic Oscillator | 14.29 | 80.00 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.